Gara Jalqabaatti › Kansarii Ovarii › Oregon › Eugene
Qorannoo klinikaalii Kansarii Ovarii Eugene, OR keessatti
Qorannoo 9 Kansarii Ovarii f Eugene fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Namoota walitti qabaa jiraSadarkaa 2
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 3
- USO - Oncology Associates of Oregon, P. C., Eugene
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Namoota walitti qabaa jiraSadarkaa 3
- Oncology Associates of Oregon, P.C., Eugene
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Namoota walitti qabaa jiraSadarkaa 3
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Oncology Associates of Oregon, P.C., Eugene
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Namoota walitti qabaa jiraSadarkaa 2
- 517, Eugene
Qorannoo Kansarii Ovarii magaalota biroo keessatti
- Houston, TXQorannoo 89
- New York City, NYQorannoo 69
- Boston, MAQorannoo 61
- Los Angeles, CAQorannoo 50
- Nashville, TNQorannoo 49
- Arlington, VAQorannoo 46
- Philadelphia, PAQorannoo 44
- Columbus, OHQorannoo 39
- St. Louis, MOQorannoo 38
- Chicago, ILQorannoo 36
- San Antonio, TXQorannoo 31
- Cleveland, OHQorannoo 30
Qorannoo biroo Eugene keessatti
- Kansara Qara'a Non-Small CellQorannoo 13
- Kansa EndometiriyaaliiQorannoo 8
- Saree OljooQorannoo 7
- Luukemiya Limfoositiikii KeessummaaQorannoo 6
- Myeloma Baay’eeQorannoo 6
- Kansara MetastatikiiQorannoo 6
- Saree (Gosoota Hunda)Qorannoo 6
- Dhibee QaraQorannoo 5
- Degenereshinii MakulaariiQorannoo 5
- Itti Fayyadama Qorannoo fi AddictionQorannoo 5
- ObesityQorannoo 4
- Baayyee UlfaataaQorannoo 3
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.